Transaction #10584 · Form 4 · 0001816160-25-000004
ACADIA PHARMACEUTICALS INC · Exercise / conversion · Common Stock
ACADIA PHARMACEUTICALS INC · Transacted November 17, 2025 · Filed November 19, 2025
What does this filing report?
An SEC Form 4 filing for ACADIA PHARMACEUTICALS INC records an exercise / conversion involving Common Stock on November 17, 2025. The reported quantity was 3,966. The filing date is November 19, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- ACADIA PHARMACEUTICALS INC
- Company CIK
- 0001070494
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 3,966
- Reported price
- Not reported · See footnotes
- Reference value
- Not reported
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 29,142
- Ownership description
- Not reported
- SEC acceptance time
- Nov 19, 2025, 6:00 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Kihara James ↗
PRINCIPAL ACCOUNTING OFFICER
CIK 0001816160
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- F2
- Includes 815 shares of the Issuer's common stock acquired by the reporting person on November 14, 2025 pursuant to an employee stock purchase plan.
- F3
- The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
- F4
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.69 to $23.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F5
- The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.
- F6
- The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.